Therapeutic angiogenesis for coronary artery disease

Annals of Internal Medicine

Volumn 136, Issue 1, 2002, Pages 54-71

  Freedman, S B ^a   Isner, J M ^a   Neely, M ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; DIPYRIDAMOLE; FIBRIN GLUE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GLYCERYL TRINITRATE; HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; PLASMID DNA; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; THALLIUM 201; VIRUS VECTOR;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOGENESIS; ANIMAL MODEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; GENE THERAPY; GENE TRANSFER; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRACORONARY INFUSION; INTRAMYOCARDIAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0036137469     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-136-1-200201010-00011     Document Type: Review

References (165)

1. Tumor angiogenesis: Therapeutic implications
2. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
3. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb
4. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
5. Direct myocardial revascularization and angiogenesis - How many patients might be eligible?
6. Differentiation of endothelium
7. Induction of vasculogenesis and hematopoiesis in vitro
8. In vitro differentiation of murine embryonic stem cells. New approaches to old problems
9. Isolation of putative progenitor endothelial cells for angiogenesis
10. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
11. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
12. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
13. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
14. Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle
15. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin
16. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability
17. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
18. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
19. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia
20. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
21. Molecular analysis of blood vessel formation and disease
22. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
23. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
24. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia
25. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of anglogenesis
26. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
27. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects
28. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
29. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease
30. Angiogenesis
31. Therapeutic angiogenesis
32. Cardiac angiogenesis and gene therapy: A strategy for myocardial revascularization
33. Mechanisms of angiogenesis and arteriogenesis
34. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: Critical role of secretion signal in use of naked DNA
35. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
36. Intracoronary gene transfer of fibroblast growth factor-4 increases regional contractile function and responsiveness to adrenergic stimulation in heart failure
37. Age-dependent impairment of angiogenesis
38. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF
39. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/-mice
40. Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation
41. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
42. Stem cell therapy and gene transfer for regeneration
43. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
44. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor
45. Preclinical and clinical studies with recombinant human basic fibroblast growth factor
46. A double-blind, placebo-controlled, phase II study of basic fibroblast growth factor in the treatment of intermittent claudication
47. Pharmacodynamics of basic fibroblast growth factor: Route of administration determines myocardial and systemic distribution
48. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
49. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion
50. Increased expression of direct gene transfer into skeletal muscles observed after acute ischemic injury in rats
51. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery
52. Collateral circulation of the heart
53. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
54. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
55. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
56. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs
57. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels
58. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts
59. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
60. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
61. Effects of acidic fiboroblast growth factor on normal and ischemic myocardium
62. Extra-cardiac to coronary anastomoses support regional left ventricular function in dogs
63. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia
64. VEGF administration in chronic myocardial ischemia in pigs
65. Vascular endothelial growth factor administration in chronic myocardial ischemia
66. Intramyocardial but not intravenous vascular endothelial growth factor improves regional perfusion in hibernating porcine myocardium
67. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
68. Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral flow to ischemic myocardium
69. Catheter-based gene transfer of VEGF utilizing electromechanical LV mapping accomplishes therapeutic angiogenesis: Pre-clinical studies in swine
70. Percutaneous electromechanical mapping demonstrates efficacy of pVGI.1 (VEGF2) in an animal model of chronic myocardial ischemia
71. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonudeic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
72. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121
73. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: Effect on myocardial angiogenesis
74. Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping
75. Percutaneous endocardial gene therapy: Patterns of in-vivo gene expression related to regional myocardial delivery
76. 121 offers equivalent gene delivery and protein expression compared to a surgical-based transepicardial injection approach
77. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia
78. Critical limb ischemia: Nothing to give at the office?
79. Arterial gene transfer of naked DNA for therapeutic angiogenesis: Early clinical results
80. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
81. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
82. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia
83. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
84. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease
85. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse
86. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
87. Coronary angiogenesis: Detection in vivo with MR imaging sensitive to collateral neocirculation - Preliminary study in pigs
88. Nonfluoroscopic, in vivo navigation and mapping technology
89. Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model
90. Coronary collateral development in swine after coronary artery occlusion
91. Use of synchrotron radiation microangiography to assess development of small collateral arteries in a rat model of hindlimb ischemia
92. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
93. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: First clinical results
94. First angiogenic treatment of coronary heart disease by FGF-1: Long-term results after 3 years
95. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
96. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronay bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
97. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis
98. Intracoronary administration of recombinant human vascular endothelial growth factor (rhVEGF) to patients with coronary artery disease
99. Results of a phase 1 open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients (pts) with severe ischemic heart disease: 6 months follow-up
100. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study
101. Effects of a single intracoronary injection of basic fibroblasr growth factor in stable angina pectoris
102. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis
103. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology
104. VIVA trial: One year follow up
105. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology
106. Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic approach in coronary heart disease
107. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease
108. Direct myocardial injection of phVEGF165: Results of complete patient cohort in phase 1/2 clinical trial
109. Effective gene transfer of phVEGF-2 for therapeutic angiogenesis in chronic myocardial ischemia as assessed by NOGA left ventricular electromechanical mapping
110. The effects of VEGF-2 gene therapy on rest and stress myocardial perfusion: Results of serial SPECT imaging
111. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
112. Video assisted epicardial delivery of angiogenic gene therapy to the human myocardium utilizing an adenovirus vector encoding for VEGF121
113. Randomized, placebo-conrtolled clinical study of percutaneous catheter-based left ventricular endocardial gene transfer of VEGF-2 for myocardial angiogenesis in patients with chronic myocardial ischemia
114. Phase I placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor-2 (VEGF-2) gene transfer utilizing catheter delivery in patients with chronic myocardial ischemia
115. Double-blind catheter-based VEGF gene transfer for myocardial ischemia. Effect on myocardial perfusion assessed by SPECT imaging
116. Intraoperative multiplane transesophageal echocardiography for guiding direct myocardial gene transfer of vascular endothelial growth factor in patients with refractory angina pectoris
117. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs. Hibernation versus stunning?
118. Hibernating myocardium
119. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium
120. Transmyocardial laser revascularisation in patients with refractory angina: A randomised controlled trial
121. Transmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomised trial
122. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
123. Transmyocardial revascularizadon with a carbon dioxide laser in patients with end-stage coronary artery disease
124. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial
125. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
126. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium
127. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia
128. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
129. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
130. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat-angiogenesis and angioma formation
131. Intramyocardial injection of DNA encoding vascular endothelial growth factor in a myocardial infarction model
132. Influence of vascular endothelial growth factor on diabetic retinopathy
133. Angiogenesis inhibitots endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
134. Stent endothelialization. Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition
135. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening
136. Local deliverry of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery
137. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer
138. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta
139. Arterial gene therapy for inhibiting restenosis in patients with claudication undergoing superficial femoral artery angioplasty
140. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty
141. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
142. Transventricular revascularization by laser
143. Angiogenesis is enhanced in ischemic canine myocardium by transmyocardial laser revascularization
144. Myocardial angiogenesis as a possible mechanism for TMLR efficacy
145. Neovascularization after transmyocardial laser revascularization in a model of chronic ischemia
146. Pathology
147. Angiogenesis in transmyocardial laser revascularization. A nonspecific response to injury
148. Histologic appearance of transmyocardial laser channels after 4 1/2 weeks
149. Histologic analysis of transmyocardial channels: Comparison of CO2 and holmium:YAG lasers
150. Laser-mediated transmural myocardial channels do not salvage acutely ischemic myocardium
151. Measurement of myocardial blood flow with positron emission tomography before and after transmyocardial laser revascularization
152. Cardiac sympathetic denervation after transmyocardial laser revascularization
153. Diagnosis, incidence, and clinical significance of early postoperative ischemia after transmyocardial laser revascularization
154. Transmyocardial laser treatment denervates canine myocardium
155. Nontransmural laser treatment incompletely denervates canine myocardium
156. Catheter-based percutaneous myocardial laser revascularization in patients with end-stage coronary artery disease
157. A randomized blinded clinical trial comparing percutaneous laser myocardial revascularization (using Biosense LV mapping) vs placebo in patients with refractory coronary ischemia
158. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors
159. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
160. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization
161. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines
162. Endothelium dysfunction in the coronary circulation
163. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia